Why AtaiBeckley (ATAI) is on investors’ radar AtaiBeckley (ATAI) has been drawing attention after a strong past 3 months for ...

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has kept Jefferies analysts bullish on the company following a fireside chat in New ...

View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen ...

That drug, tagged BPL-003 by Atai, is an antidepressant that was recently evaluated in an open-label phase 2a study. The company is developing the medication in collaboration with a privately held ...

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a ...

atai Life Sciences (NASDAQ:ATAI) on Thursday announced Invyxis, a new program to accelerate the company’s portfolio of compounds. What Happened: The clinical-stage biotechnology company focused on ...

atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health The Fund aims to help ...